ARDX Ardelyx
WatchlistArdelyx News
The 15% Return This Week Takes Ardelyx's (NASDAQ:ARDX) Shareholders One-year Gains to 109%
Unless you borrow money to invest, the potential losses are limited. But if you pick the right business to buy shares in, you can make more than you can lose. Take, for example Ardelyx, Inc. (NASDAQ
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class m
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
Ardelyx(ARDX.US) Officer Sells US$99,997.5 in Common Stocks
$Ardelyx(ARDX.US)$ Officer Williams Laura A sold 25,000 shares of Common Stocks on Nov 15, 2023 at an average price of $3.9999 for a total value of $99,997.5.Source: Announcement What is statement of
Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia
Ardelyx Gets FDA Orphan Drug Designation for Pediatric Xphozah
XPHOZAH Granted Orphan Drug Designation By U.S. FDA For The Treatment Of Pediatric Hyperphosphatemia
XPHOZAH Granted Orphan Drug Designation By U.S. FDA For The Treatment Of Pediatric Hyperphosphatemia
Ardelyx (NASDAQ:ARDX) Shareholders Have Earned a 226% Return Over the Last Year
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), Gamida Cell (GMDA) and Ardelyx (ARDX)
Ardelyx to Participate at the Jefferies London Healthcare Conference
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
5 OTC Stocks With The Potential To Explode In 2024
Despite the risk, investing in over-the-counter (OTC) stocks remains popular for one reason: the potential for a massive return on investment. While there's no way of knowing what 2024 will hold — esp
Promising Prospects for Ardelyx's XPHOZAH Drive Buy Rating: An Analysis of Market Potential and Commercial Traction
Ardelyx Announces XPHOZAH (Tenapanor) Now Available in the United States
XPHOZAH is the first and only FDA approved phosphate absorption inhibitor Best-in-class patient services programs support patient access and affordability for XPHOZAH patients WALTHAM, Mass., Nov. 06, 2023 (GLOBE
Ardelyx Shares Positive Data From Studies of XPHOZAH (Tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
HC Wainwright & Co. Maintains Buy on Ardelyx, Raises Price Target to $11
HC Wainwright & Co. analyst Ed Arce maintains Ardelyx with a Buy and raises the price target from $9 to $11.
Ardelyx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/01/2023 184.61% HC Wainwright & Co. $9 → $11 Maintains Buy 09/13/2023 81.11% Wedbush → $7 Reiterates Ou
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript
Institutional Investors Have a Lot Riding on Ardelyx, Inc. (NASDAQ:ARDX) With 59% Ownership
Key Insights Given the large stake in the stock by institutions, Ardelyx's stock price might be vulnerable to their trading decisions 50% of the business is held by the top 23 shareholders Inside
Earnings Call: Ardelyx Reports Robust Q3 Growth, Plans for New Drug Launch
Piper Sandler Keeps Their Buy Rating on Ardelyx (ARDX)